Last reviewed · How we verify
Augmentin®
Augmentin combines amoxicillin (a beta-lactam antibiotic) with clavulanic acid (a beta-lactamase inhibitor) to kill bacteria and overcome antibiotic resistance.
Augmentin combines amoxicillin (a beta-lactam antibiotic) with clavulanic acid (a beta-lactamase inhibitor) to kill bacteria and overcome antibiotic resistance. Used for Bacterial infections of the ear, nose, and throat, Respiratory tract infections, Urinary tract infections.
At a glance
| Generic name | Augmentin® |
|---|---|
| Also known as | laparoscopy, Experimental: Augmentin, Augmentin 3 tablets (Amoxicilin:clavualanate=2:1) bid, for 14days, the reference product |
| Sponsor | Teva Pharmaceuticals USA |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Bacterial penicillin-binding proteins (PBPs); beta-lactamase enzymes |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin works by inhibiting bacterial cell wall synthesis through penicillin-binding proteins. Clavulanic acid irreversibly binds to and inactivates beta-lactamase enzymes produced by resistant bacteria, preventing them from destroying amoxicillin and allowing the antibiotic to remain effective against otherwise resistant gram-positive and gram-negative organisms.
Approved indications
- Bacterial infections of the ear, nose, and throat
- Respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
- Bone and joint infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Abdominal pain
- Allergic reaction/anaphylaxis
Key clinical trials
- Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use (NA)
- Effect of Bifidobacterium Breve PRL2020 (an Amoxicillin-clavulanate-resistant Strain) on Gastrointestinal Symptoms and Gut Microbiota Composition in Children Treated With Amoxicillin or Amoxicillin/Clavulanate (NA)
- A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects (NA)
- Evaluation of Bifidobacterium Breve PRL2020 in Preventing Antibiotic-Associated Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid (NA)
- LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media (NA)
- Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Conditions (PHASE1)
- Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Fasting Conditions (PHASE1)
- Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |